Dupixent fda approval status 2026?

I can’t confirm real-time FDA status for 2026 from here. My latest update covers approvals up to about 2024, and Dupixent (dupilumab) has FDA approvals for several indications, with ongoing label expansions over time. Here are the main approved uses you’d typically see mentioned:

- Atopic dermatitis (AD): approved for adults and for pediatric patients (dates and ages have expanded over the years).
- Chronic rhinosinusitis with nasal polyps (CRSwNP): approved in adults (and later updates may include adolescents in some regions/labels).
- Asthma: approved for adults and adolescents aged 12 and up (with specific dosing/age ranges in the label).
- Eosinophilic esophagitis (EoE): approved for adults and adolescents aged 12 and older.
- Prurigo nodularis (PN): approved for adults.

If you want, I can help you verify the exact, current FDA status for a particular indication and age group as of 2026. Tell me which indication and which age range you’re interested in (for example: “Dupixent for eosinophilic esophagitis in adults” or “Dupixent for asthma in adolescents 12–17”), and I’ll outline the latest labeling details and approvals. You can also check directly with FDA’s Drugs@FDA database or Regeneron/Sanofi press releases for the most up-to-date information.